Abstract: The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and a physiologically active polypeptide modified with the branched polyalkylene glycol.

Abstract: The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and a physiologically active polypeptide modified with the branched polyalkylene glycol.

Abstract: The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and a physiologically active polypeptide modified with the branched polyalkylene glycol.

Abstract: The present invention relates to a fusion polypeptide which comprises a polypeptide having G-CSF activity and a polypeptide having TPO activity and DNA which codes for the fusion polypeptide, to a fusion polypeptide in which a polypeptide having G-CSF activity and a polypeptide having TPO activity are fused via a spacer peptide and DNA which codes for the fusion polypeptide and to a polypeptide in which the fusion polypeptide comprising a polypeptide having G-CSF activity and a polypeptide having TPO activity is chemically modified with a polyalkylene glycol derivative. It also relates to an anemia-treating composition containing the fusion polypeptide as an active ingredient.

Abstract: The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and a physiologically active polypeptide modified with the branched polyalkylene glycol.

Abstract: A rotary cooling roller includes outer and inner cylinders, two end plates fixed to both ends of the outer cylinder, and a supporting shaft protruding from the end plates. A cylindrical space, provided between the outer and the inner cylinders, communicates with the inner space of the inner cylinder via through-holes formed in the inner cylinder. A coolant contained is allowed to flow back and forth between the cylindrical space and the inner space of the inner cylinder. Ring-shaped spacers are provided in the cylindrical space for passing an external force exerted on the outer cylinder to the inner cylinder.

Abstract: The present invention provides branched polyalkylene glycols useful as a chemically modifying agent for physiologically active polypeptides, wherein two single-chain polyalkylene glycols are linked to a group having a cyclic structure other than a plane structure, and wherein a group having reactivity with an amino acid side chain, an N-terminal amino group or a C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity is linked to the group having a structure other than a plane structure.

Abstract: A rotary cooling roller includes outer and inner cylinders, two end plates fixed to both ends of the outer cylinder, and a supporting shaft protruding from the end plates. A cylindrical space, provided between the outer and the inner cylinders, communicates with the inner space of the inner cylinder via through-holes formed in the inner cylinder. A coolant contained is allowed to flow back and forth between the cylindrical space and the inner space of the inner cylinder. Ring-shaped spacers are provided in the cylindrical space for passing an external force exerted on the outer cylinder to the inner cylinder.

Abstract: Described herein is a pyrrolocarbazole derivative and a pharmaceutically acceptable salt thereof having the following formula (I): ##STR1## wherein R.sup.1 is lower alkyl or aralkyl; R.sup.2 is hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, or substituted or unsubstituted aralkyl; R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 may be the same or different, and are hydrogen, halogen, nitro, substituted or unsubstituted lower alkanoyl, NR.sup.9 R.sup.10, or OR.sup.11 ; R.sup.8 is hydrogen or is combined with R.sup.3 to form --CONR.sup.12 --; and when R.sup.1 is benzyl; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are not simultaneously hydrogen. A compound of the present invention stimulates platelet production and is useful for treatment of thrombocytopenia.

Abstract: 3, 3", 4"-Tri-O-acylspiramycin I represented by the formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different groups, and at least one of the groups is a straight or branched chain alkylcarbonyl group represented by --COC.sub.m H.sub.2m+1 wherein m is an integer of 2-4 and the other group(s) are straight or branched chain alkylcarbonyl group(s) represented by --COC.sub.n H.sub.2n+1 wherein n is an integer of 1-4, and its pharmacologically acceptable acid addition salts.